診斷與治療

(檢測試劑)

精準檢測·即刻反應





瑞基海洋生物科技股份有限公司

GeneReach Biotechnology Corporation

www.genereach.com/tw/index.php

PRODUCTS

瑞基自動化核酸分析儀 / POCKIT Central 瑞基新型冠狀病毒 (orf 1ab) 檢測試劑

POCKIT Central Nucleic Acid Analyzer /
POCKIT Central SARS-CoV-2 (orf 1ab) Premix Reagent

瑞基自動化核酸分析儀完美的整合磁珠核酸萃取、機器手臂移液科技,以及 iiPCR 核酸擴增技術,將整個核酸檢驗流程簡化成樣品進結果出的設計,使用者只需要簡單的放入樣品,按下啟動鍵,便可以於 85 分鐘後得到品質等同於一流檢驗實驗室的結果,顛覆核酸檢驗總是和昂貴、繁瑣、和必須由專業人員操作的刻板印象,可滿足多元化市場對於疾病預防、早期診斷、及生物安全防護的需求。產品獲得國內外醫療器材認證,包含台灣衛福部及歐盟 CE-IVD 認證。

POCKIT™ Central offers an affordable and fully automated molecular testing platform by combining magnetic bead-based nucleic acid extraction, robotic arm liquid transfer, and iiPCR nucleic acid amplification to meet every molecular testing need worldwide. POCKIT™ Central is a sample-to-answer platform that simplifies the nucleic acid testing process. Users simply add samples, tap the screen, and after 85 minutes, the lab-equivalent results

are ready. Complicated operation procedure and human operation error are eliminated. Sophisticated nucleic acid testing becomes easy, affordable and available anywhere, anytime. The POCKIT Central COVID-19 assay has obtained EUA from Taiwan FDA and has been CE marked.



CONTACT

蔡傳馥 Mark Tsai

+886-4-2463-9869#1223 / marktsai@genereachbiotech.com



Barcoded Magnetic Beads | Highly Multiplexed Assays

瑞磁生物科技股份有限公司

Applied BioCode

www.apbiocode.com/tw/index.htm

P R O D U C T S

新冠肺炎檢測試劑

BioCode® SARS-Cov-2 Assay

多元呼吸道診斷試劑

BioCode® Respiratory Panel

多元腸胃道診斷試劑

BioCode® Gastrointestinal Panel

自動化分子診斷系統

BioCode® MDx3000

瑞磁生技致力於傳染性疾病體外診斷試劑與儀器的研發和製造。 以精準度最高的核酸 檢測有效檢出新冠肺炎,以及傳統上各種難以迅速鑑別的病毒、細菌、寄生蟲。 提供 多元、精準的診斷資訊給臨床醫師,為患者提供最適當的療程。

Applied BioCode is dedicated in developing and manufacturing In-Vitro diagnostics assay kit and instrument for infectious disease diagnostics. By using the highest accuracy nucleic acid detection method, we effectively identify SARS-Cov-2 and other traditionally difficult to catch pathogens, including virus, bacteria and parasites. We provide multiplex and accurate diagnostics information to physicians, resulting the most suitable treatment for patients.

CONTACT

唐琳鈞 Anthony Tang +886-988-959-997 / Ictang@apbiocode.com



博錸生技股份有限公司

PlexBio Co., Ltd.

www.tw.plexbio.com/index.aspx?lang=zh

P R O D U C T S

博錸新型冠狀病毒核酸檢驗試劑

IntelliPlex SARS-CoV-2 Detection Kit

以精準醫療癌症監控及管理為主要產品開發領域的博錸生技,此次以新冠肺炎病毒核酸檢測試劑跨入傳染性疾病檢測領域,即獲歐盟 CE-IVD、美國 FDA EUA 資格與衛福部專案製造許可。下一步,博錸將完成結合新冠肺炎、A 型流感、B 型流感的聯檢試劑,以因應下一波疫情,同時持續深化傳染性疾病相關試劑研發,努力實踐博錸以創新的多重檢測技術促進人類福祉的使命。

PlexBio has now obtained US FDA EUA, CE Mark (IVD) in the European Union and TFDA EUA for its IntelliPlex SARS-CoV-2 Detection kit. We are proud that our efforts on the SARS-CoV-2 assay further enable rapid and early diagnosis to help manage infected patients and contribute overall to the global efforts to control the COVID-19 pandemic. PlexBio will work with its various regional partners to introduce this high throughput and sensitive testing solution to the US and EU markets as well the Asia-Pacific region.



CONTACT

黃奕達

+886-2-2627-5878#180 / clement.h@plexbio.com





財團法人工業技術研究院 生醫所

Industrial Technology Research Institute

www.itri.org.tw

PRODUCTS

iPMx 分子快速檢驗系統(疫開罐)

iPMx Molecular Rapid Test System

iPMx 分子快速檢驗系統(疫開罐)

小型化的手持式分子檢測系統,跳脫傳統龐大加熱模組方式,改以創新機構設計搭配溫度控制手段實現聚合酶鏈鎖反應 (PCR),不需要移動物件或其他複雜控制裝置,即可有效率地達到核酸擴增條件,並研發專屬的光學即時偵測模組,可達到定性或半定量快速檢測,最快可於30分鐘內得到定性判別結果。適用於各醫護或檢測點,結合試劑開發發展病毒或細菌之感染性疾病、基因變異、農漁牧及基改食品等各類分子診斷應用。

iPMx Molecular Rapid Test System

Instead of the regular Polymerase Chain Reaction (PCR) systems with thermocycler for heating and cooling, ITRI uses innovative heating control methodology to fulfill rapid temperature control and perform both DNA and RNA amplification with a portable and easy-to-operate PCR system. With an innovative designed optical detection module, the whole system can achieve qualitative or semi-quantitative rapid detection for PCR within 30 minutes. In the near future, this system can be applied to clinics, agricultural, aquaculture and GMO testing.





CONTACT

陳庭軒 Ting-Hsuan Chen +886-3-591-3007 / Ting-HsuanChen@itri.org.tw

寶齡富錦生技股份有限公司

Panion & BF Biotech Inc.

www.pbf.com.tw

PRODUCTS

飛確 新型冠狀病毒抗原快速檢驗試劑

Vstrip Covid-19 Antigen Rapid Test

透過快速免疫色譜分析法,用於定性檢測 COVID-19 疑似症狀出現 5 天內之患者,其鼻咽拭子是否具有 SARS-CoV-2 核衣殼蛋白抗原。

試劑用於檢測新型冠狀病毒核衣殼蛋白抗原,此類抗原通常會存在於感染急性期的上呼吸道檢體中。當呈現陽性結果時,表示檢體中存在病毒抗原,但須搭配患者病史與其他臨床數據合併評估感染狀態。本試劑旨在供受過訓練的臨床實驗室人員使用,這些人員經過專業體外診斷程序的訓練。

Vstrip COVID-19 Antigen Rapid Test is a rapid in vitro immunochromatographic assay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2

in nasopharyngeal swab from individuals who are suspected of COVID-19 by their healthcare provider within the first five days of the onset of symptoms.

Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. This antigen is generally detectable in upper respiratory samples during the acute phase of infection. The Vstrip COVID-19 Antigen Rapid Test is intended for use by trained clinical laboratory personnel specifically instructed and trained in vitro diagnostic procedures.



CONTACT

方穎惠 Lisa Fang

+886-975-387-935 / lisa.fang@pbf.com.tw



凌越生醫股份有限公司

Excelsior Bio-System Incorporation

www.ebs.com.tw

PRODUCTS

凌越新型冠狀病毒抗體快速檢測試劑

ALERT SARS-CoV-2 Antibody Rapid Test

本產品是一種基於免疫色層分析法的定性試劑,用於檢測人體血漿或血清中所含有的新型冠狀病毒抗體。雖然在感染過程中的抗體濃度尚未被瞭解的很完整,但目前檢測結果可用於檢測 SARS-CoV-2 抗體。IgG 和 IgM 的陽性結果可能在感染後發生,並被視為是急性或近期內感染。檢測陰性的結果則不能排除 SARS-CoV-2 感染的可能性,因此不應視作為患者管理決策的唯一依據。檢驗結果必須結合臨床觀察、患者病史和流行病學來做整體判斷。

The ALERT SARS-CoV-2 Antibody Rapid Test is a lateral flow immunoassay intended for qualitative detection of total antibody to SARS-CoV-2 in human serum and plasma (EDTA and heparin).

The test results must be combined with clinical observation, patient history and epidemiology to make an overall judgment.





CONTACT

蘇建宏 Mike Su

+886-2-2796-2656#2519 / mike.su@ebs.com.tw



長興材料工業股份有限公司

Eternal materials Co., Ltd.

www.eternal-group.com/Home/ChtIndex

PRODUCTS

長興 COVIDual COVID-19 抗體檢測試劑

Eternal COVIDual COVID-19 antibody Rapid Test

長興 COVIDual COVID-19 抗體檢測試劑為一定性檢測及偵測全血、血清或血漿樣品(含肝素鈉、檸檬酸鈉、或 EDTA)中辨識 SARS-CoV-2 核蛋白之 IgM 及 IgG 抗體的側向流免疫層析裝置。結合臨床表現及其他實驗室測試結果,本檢測試劑可做為診斷疑似感染 SARS-CoV-2 患者的輔助工具。此檢測試劑具有超過 93% 的專一性及 94% 的靈敏度(發病後 14 天採血檢體 ELISA 與此產品檢測一致性),於 15-20 分內即可協助評估曾接觸過病毒病患的免疫反應。

The Eternal COVIDual COVID-19 antibody Rapid Test is a lateral flow immunoassay intended for the qualitative detection of IgM and IgG antibodies to SARS-CoV-2 in whole blood, serum, or plasma (containing sodium heparin, sodium citrate, or EDTA) specimens from patients suspected of SARS-CoV-2 infection by a healthcare provider. The COVIDual COVID-19 antibody Rapid Test is an aid in the diagnosis of patients with suspected SARS-CoV-2 infection in conjunction with clinical presentation and the results of other laboratory tests.

The Eternal COVIDual COVID-19 antibody Rapid Test has a specificity greater than 93% and sensitivity of 94% (>14 Days form symptom onset to blood collection; the agreement between ELISA and this product). This test can contribute to evaluate patients 'immune response to the virus in 15-20 minutes if a person has been exposed to the virus and developed antibodies.

CONTACT

陳玟瑾 Tiffany Chen

+886-7-383-8181#629 / tiffany_chen@eternal-group.com



亞洲基因科技股份有限公司

AsiaGen Corporation

www.asiagen.com.tw

PRODUCTS

登革熱、肺結核、MPT64 抗原、A/B 流感、驗孕排卵快速檢驗試劑、新冠狀肺炎抗原快篩試劑、新冠狀肺炎抗體快篩試劑

Dengue NS1 \ TB \ TBAg MPT64 \ Influenza A/B \ Pregnany/Ovulation Rapid Test \ Covid-19 Antigen Rapid Test Covid-19 Human IgG/IgM Rapid Test

亞洲基因主要經營策略為發展液態晶片 (Liquid Array) 技術平臺,並運用自行建立的 RAPID Array®(以磁珠技術為主)及 Mobile Array®(以 Luminex®技術為主)等技術平臺,開發、量產及行銷一系列之核酸探針檢驗試劑,以檢驗各種傳染病及癌症,並陸續開發出登革熱、肺結核、A/B 流感、驗孕排卵檢驗試劑測試組合等多項先進檢驗試劑。目前也正積極發展相關 Covid-19 新冠狀病毒檢測快篩試劑,以達成盡早檢測降低感染發生率。

AsiaGen Corporation whose strategy is to explore the core technology of "Liquid Array" and has successfully established RAPID Array® (magnetic beads-based), Mobile Array® (Luminex®-based) and Hybrid Strip™ Technologies. By using these proprietary technologies, AsiaGen is developing, manufacturing and marketing a series of molecular probing kits for a variety of infectious diseases and cancers based on genomic study. We successively developed a number of advanced test, such as dengue virus, tuberculosis, A/B influenza, pregnancy and ovulation rapid test. At present, it is also actively developing related Covid-19 rapid test to achieve early detection and reduce the incidence of infection.





CONTACT

黃芸萱 Lily Huang

+886-921-675-298 / lili@asiagen.com.tw